Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, United States of America.
PLoS One. 2011;6(11):e27171. doi: 10.1371/journal.pone.0027171. Epub 2011 Nov 14.
The mechanism by which HIV and HCV cooperatively accelerate hepatocyte damage is not clearly understood; however, each virus affects the TRAIL: TRAIL-receptor system. We, therefore, questioned whether the independent effects of HCV and HIV combine to synergistically result in TRAIL dependent hepatocyte killing. We describe that Huh7 hepatocytes treated with HIV gp120 results in both increase TRAIL-R2 expression and an acquired sensitivity to TRAIL mediated killing. Moreover HCV infection and HCV core expression alone in Huh7 cells upregulates TRAIL. Co-incubation of HIV gp120 primed hepatocytes with HCV core expressing hepatocytes results in the selective death of the HIV gp120 primed hepatocytes that is selectively blocked by TRAIL-R2-Fc fusion protein. Liver biopsies from HIV mono-infected patients have increased TRAIL-R2; biopsies from HCV infected patients have increased TRAIL, while co-infected liver biopsies have increased PARP cleavage within hepatocytes indicating enhanced apoptosis. These findings suggest a pathogenic model to understand why HIV/HCV co-infection accelerates liver injury.
HIV 和 HCV 协同加速肝细胞损伤的机制尚不清楚;然而,每种病毒都会影响 TRAIL:TRAIL 受体系统。因此,我们质疑 HCV 和 HIV 的独立作用是否会协同导致 TRAIL 依赖性肝细胞杀伤。我们描述了 HIV gp120 处理的 Huh7 肝细胞导致 TRAIL-R2 表达增加和对 TRAIL 介导的杀伤的获得性敏感性。此外,HCV 感染和单独在 Huh7 细胞中表达 HCV 核心上调 TRAIL。HIV gp120 预激活的肝细胞与表达 HCV 核心的肝细胞共孵育导致 HIV gp120 预激活的肝细胞选择性死亡,而 TRAIL-R2-Fc 融合蛋白可选择性阻断这种死亡。HIV 单感染患者的肝活检显示 TRAIL-R2 增加;HCV 感染患者的肝活检显示 TRAIL 增加,而合并感染的肝活检显示肝细胞内 PARP 切割增加,表明凋亡增强。这些发现提出了一个发病机制模型,以了解为什么 HIV/HCV 合并感染会加速肝损伤。